Head-to-head · WeighScore
AM Rx vs ReadyRx
The verdict
ReadyRx takes it — 67.6/100 to 49.6/100.
ReadyRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. ReadyRx (readyrx.com) is a LegitScript-certified US telehealth provider offering compounded semaglutide from $179/mo and compounded tirzepatide from $255/mo, plus NAD+, sermorelin, glutathione, MIC+B12, and…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | AM Rx | ReadyRx |
|---|---|---|
| WeighScore | 49.6/100 | 67.6/100 |
| Grade | C | C |
| Scorecard rank | #491 | #168 |
| Semaglutide | $151/mo (quarterly plan, plus a separate fee, compounded) | $179/mo (starting dose, compounded) |
| Tirzepatide | Not disclosed | $255/mo (starting dose, compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #491 · C
Strengths
- Insurance coordination for brand-name GLP-1s — as low as $25/mo
- All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
- HSA and FSA accepted
- Video visits available with providers averaging 10+ years' experience
- Compounded semaglutide from $151/mo on the quarterly plan
Where it loses points
- Active FTC/DOJ lawsuit over deceptive billing and subscription practices
- Novo Nordisk false-advertising lawsuit (Aug 2025)
- Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
- Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #168 · C
Strengths
- LegitScript Certified — verifiable via the badge link in the footer
- Batch lab testing covers the right QA metrics for injectables: potency, sterility, pH, and endotoxicity
- Pricing shown publicly: $179/mo semaglutide, $255/mo tirzepatide
Where it loses points
- Pharmacy partners not named — only described as 'FDA-registered compounding pharmacies'
- Clinicians described as licensed and board-certified, but no names or credentials published
- 5,000+ member figure comes from a directory listing, not an independent audit
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.